The ATTD of DM decreased then increased (linear, P = 0.001; quadratic, P = 0.003) as TIU/mg of complete feed increased in the ...

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -- Reported highly ...

The drug, delivered by EMS as a single injection, improved infarct-related patency at cath lab arrival and 30-day clinical outcomes.

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM ESTCompany ParticipantsAngela Wirick - Chief Financial ...

Doctors have always told patients with atrial fibrillation (AF) to limit caffeine, saying it could trigger irregular heartbeats, however, a new international trial shows that moderate coffee intake is ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update 100 Patients Enrolled in Phase 2b Trial of Halneuron®; Interim ...

Modern semiconductor chip design faces growing complexity due to numerous timing scenarios driven by varying operating ...

Shift verification effort from a single, time-consuming flat run to a more efficient, distributed, and scalable process.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results cons ...

Adequate management of COPD is important because hospitalisation for an acute exacerbation of COPD (AECOPD) is associated ...